1 of 1
Story summary
- Lawmakers urge CMS Administrator Dr. Mehmet Oz to withdraw the fixed-dose combination policy.
- More than 50 bipartisan members sent a Sept. 21 letter demanding CMS not finalize the rule.
- Lawmakers argue the policy would push new drug versions into Medicare price negotiations immediately after FDA approval.
- CMS says the proposal prevents drugmakers from evading negotiated prices by limiting changes to existing drugs.